
  
    
      
        Background_NNP
        Hotspots_NNP have_VBP been_VBN defined_VBN as_IN the_DT minimal_JJ functional_JJ
        protein_NN :_: protein_NN interaction_NN domains_NNS through_IN which_WDT
        biological_JJ activity_NN can_MD be_VB modulated_JJ [_NN 1_CD 2_CD 3_CD ]_NN ._. A_DT novel_NN
        strategy_NN called_VBD Phenogenix_NNP ®_NN has_VBZ been_VBN developed_VBN as_IN a_DT means_NN
        for_IN studying_VBG these_DT interactions_NNS ._. To_TO enable_VB Phenogenix_NNP ®_NN ,_, we_PRP
        use_VBP large_JJ and_CC diverse_JJ phage_NN display_NN libraries_NNS consisting_VBG of_IN
        randomized_JJ 20_CD mer_NN and_CC 40_CD mer_NN amino_JJ acid_NN peptides_NNS with_IN >_NN
        10_CD 11_CD independent_JJ clones_NNS ._. Because_IN of_IN their_PRP$ ability_NN to_TO
        modulate_VBP protein_NN :_: protein_NN interactions_NNS ,_, the_DT resulting_VBG
        peptides_NNS are_VBP called_VBN Hotspot_NNP Ligands_NNP (_( HSPLs_NNP )_) ._. Using_VBG this_DT
        approach_NN ,_, we_PRP have_VBP successfully_RB identified_VBN peptide_NN agonists_NNS
        and_CC antagonists_NNS for_IN a_DT number_NN of_IN biologically_RB important_JJ
        molecules_NNS including_VBG growth_NN hormone_NN receptor_NN ,_, insulin_NN
        receptor_NN and_CC the_DT insulin-like_JJ growth_NN factor_NN receptor_NN [_NN 2_CD 3_CD
        ]_NN ._.
        In_IN this_DT report_NN ,_, we_PRP describe_VBP the_DT use_NN of_IN Phenogenix_NNP ®_NN to_TO
        identify_VB the_DT critical_JJ protein_NN :_: protein_NN interactions_NNS
        underlying_VBG the_DT TNF_NNP /_NN TNFR_NNP axis_NNS ._. TNFα_NNP and_CC TNFβ_NNP have_VBP been_VBN
        extensively_RB studied_VBN and_CC are_VBP involved_VBN in_IN immune_JJ and_CC
        pro-inflammatory_JJ responses_NNS ,_, playing_VBG an_DT important_JJ role_NN in_IN
        host_NN defenses_NNS against_IN infection_NN and_CC other_JJ disease_NN states_NNS [_NN
        4_CD 5_CD 6_CD 7_CD ]_NN ._. The_DT biological_JJ effects_NNS of_IN TNFα_NNP and_CC TNFβ_NNP are_VBP
        mediated_JJ through_IN the_DT two_CD membrane_NN associated_VBN receptors_NNS ,_,
        TNFR_NNP 1_CD (_( p_NN 55_CD )_) and_CC TNFR_NNP 2_CD (_( p_NN 75_CD )_) ,_, that_WDT are_VBP expressed_VBN on_IN the_DT
        target_NN cells_NNS [_NN 8_CD 9_CD ]_NN ._. The_DT postulated_JJ pathogenic_JJ roles_NNS for_IN
        TNF_NNP include_VBP sepsis_NN and_CC other_JJ bacterial_JJ and_CC viral_JJ
        pathologies_NNS [_NN 10_CD 11_CD 12_CD ]_NN ,_, certain_JJ cancers_NNS [_NN 13_CD ]_NN ,_,
        metastasis_NNS [_NN 14_CD ]_NN and_CC chronic_JJ autoimmune_JJ disorders_NNS such_JJ as_IN
        rheumatoid_NN arthritis_NN [_NN 15_CD 16_CD ]_NN ,_, multiple_JJ sclerosis_NN [_NN 17_CD ]_NN
        and_CC Crohn_NNP 's_POS disease_NN [_NN 18_CD ]_NN ._. It_PRP is_VBZ worth_JJ noting_VBG that_IN TNFα_NNP
        mutants_NNS have_VBP been_VBN identified_VBN that_IN selectively_RB bind_NN TNFR_NNP 1_CD ._.
        One_CD such_JJ mutant_JJ induced_VBN less_RBR systemic_JJ toxicity_NN yet_RB showed_VBD
        no_DT compromise_NN in_IN its_PRP$ anti-tumor_JJ activity_NN in_IN nude_JJ mice_NNS [_NN 13_CD
        ]_NN ._. These_DT observations_NNS indicated_VBD that_IN finding_VBG modulators_NNS
        specific_JJ for_IN each_DT of_IN the_DT TNF_NNP receptors_NNS is_VBZ indeed_RB
        possible_JJ ._.
        While_IN TNFα_NNP binds_NNS equally_RB well_RB to_TO both_DT receptors_NNS ,_, the_DT
        majority_NN of_IN biologic_JJ responses_NNS attributed_VBD to_TO TNF_NNP are_VBP
        mediated_JJ via_IN TNFR_NNP 1_CD although_IN there_EX is_VBZ evidence_NN that_DT
        activation_NN of_IN TNFR_NNP 2_CD is_VBZ responsible_JJ for_IN some_DT adverse_JJ effects_NNS
        of_IN TNFα_NNP [_NN 19_CD 20_CD 21_CD 22_CD 23_CD 24_CD ]_NN ._. Thus_RB ,_, the_DT differential_NN
        regulation_NN of_IN these_DT two_CD receptors_NNS may_MD require_VB drugs_NNS that_WDT
        specifically_RB target_NN either_CC TNFR_NNP 1_CD or_CC TNFR_NNP 2_CD allowing_VBG
        therapeutic_JJ efficacy_NN without_IN the_DT expected_VBN toxicity_NN profile_NN ._.
        One_CD obvious_JJ possibility_NN then_RB is_VBZ to_TO search_VB for_IN Surrogates_NNP
        that_IN selectively_RB bind_NN and_CC regulate_VB the_DT individual_JJ
        receptors_NNS ._. To_TO date_NN several_JJ antagonistic_JJ protein_NN reagents_NNS
        have_VBP been_VBN isolated_VBN for_IN treating_VBG diseases_NNS with_IN an_DT underlying_VBG
        TNF_NNP etiology_NN ._. These_DT include_VBP neutralizing_VBG monoclonal_NN
        antibodies_NNS and_CC soluble_JJ forms_NNS of_IN TNFR_NNP 1_CD and_CC TNFR_NNP 2_CD [_NN 25_CD 26_CD 27_CD
        ]_NN ._. However_RB ,_, both_DT antibodies_NNS and_CC extracellular_NN receptors_NNS
        are_VBP large_JJ proteins_NNS and_CC not_RB amenable_JJ to_TO oral_JJ administration_NN ._.
        They_PRP also_RB carry_VBP the_DT unwanted_JJ risk_NN of_IN stimulating_VBG an_DT
        auto-immune_JJ response_NN during_IN chronic_JJ use_NN ._.
        By_IN panning_VBG our_PRP$ peptide_NN libraries_NNS against_IN the_DT TNFR_NNP 2_CD ,_, we_PRP
        isolated_VBD four_CD HSPL_NNP peptides_NNS binding_JJ specifically_RB to_TO human_JJ
        TNFR_NNP 2_CD that_WDT allow_VBP the_DT subdivision_NN of_IN the_DT receptor_NN into_IN a_DT
        minimum_NN of_IN at_IN least_JJS three_CD independent_JJ hotspots_NNS involved_VBN in_IN
        its_PRP$ interaction_NN with_IN TNFα_NNP ._. In_IN a_DT biological_JJ model_NN for_IN TNFα_NNP
        activation_NN of_IN TNFR_NNP 2_CD ,_, three_CD of_IN the_DT four_CD peptides_NNS induced_VBD
        cytotoxic_JJ response_NN in_IN the_DT target_NN cell_NN line_NN suggesting_VBG that_IN
        at_IN least_JJS one_CD of_IN these_DT domains_NNS induced_VBD a_DT unique_JJ
        TNFR_NNP 2_CD -_: specific_JJ biological_JJ response_NN ._. Overall_RB ,_, these_DT data_NNS
        show_VBP the_DT utility_NN of_IN using_VBG the_DT HSPL_NNP peptides_NNS for_IN subdividing_VBG
        protein_NN :_: protein_NN interacting_VBG domains_NNS and_CC for_IN defining_VBG unique_JJ
        novel_NN biological_JJ activities_NNS not_RB observed_VBD through_IN the_DT
        natural_JJ ligand_NN /_NN receptor_NN interaction_NN ._.
      
      
        Results_NNS
        Human_NNP TNFR_NNP 2_CD was_VBD panned_VBN with_IN random_JJ 20_CD mer_NN and_CC 40_CD mer_NN
        phage_NN display_NN peptide_NN libraries_NNS of_IN high_JJ diversity_NN [_NN 2_CD 3_CD 28_CD
        ]_NN ._. After_IN four_CD rounds_NNS of_IN panning_VBG ,_, four_CD phage_NN clones_NNS were_VBD
        isolated_VBN with_IN specificity_NN for_IN TNFR_NNP 2_CD ._. The_DT peptides_NNS were_VBD
        initially_RB divided_VBN into_IN two_CD groups_NNS :_: a_DT 40_CD mer_NN designated_VBN
        KcF_NNP 12_CD and_CC three_CD 20_CD mers_NNS designated_VBN KcC_NNP 7_CD ,_, KcD_NNP 11_CD and_CC KcF_NNP 6_CD
        (_( Table_NNP 1_LS )_) ._. From_IN the_DT amino_JJ acid_NN sequences_NNS ,_, KcC_NNP 7_CD ,_, KcD_NNP 11_CD and_CC
        KcF_NNP 12_CD were_VBD found_VBN to_TO have_VB a_DT pair_NN of_IN cysteine_NN residues_NNS
        suggesting_VBG the_DT possibility_NN of_IN intra-chain_JJ disulfide_NN
        bonding_NN ._. In_IN addition_NN ,_, a_DT putative_JJ motif_NN ,_, 
        W_NNP x_SYM 
        EY_NNP xx_NN 
        RGG_NNP ,_, was_VBD found_VBN for_IN peptides_NNS KcF_NNP 6_CD and_CC
        KcD_NNP 11_CD (_( Table_NNP 1_LS )_) ._. It_PRP was_VBD interesting_JJ that_IN this_DT motif_NN was_VBD
        related_VBN to_TO a_DT sequence_NN 
        W_NNP x_SYM 
        E_NNP xxxxx_NN 
        GG_NNP found_VBD at_IN the_DT C-_NNP terminal_NN (_( amino_JJ acids_NNS
        190_CD -_: 198_CD )_) of_IN TNF-α_NNP ._. No_DT appreciable_JJ sequence_NN homology_NN was_VBD
        seen_VBN between_IN either_DT of_IN the_DT natural_JJ ligands_NNS ,_, TNFα_NNP or_CC TNFβ_NNP ,_,
        and_CC KcF_NNP 12_CD although_IN the_DT spacing_VBG of_IN cysteine_NN loop_NN was_VBD close_RB
        to_TO that_DT seen_VBN in_IN the_DT cysteine_NN rich_JJ domains_NNS of_IN TNFR_NNP 2_CD [_NN 29_CD ]_NN ._.
        At_IN present_JJ ,_, it_PRP is_VBZ not_RB known_VBN whether_IN these_DT structural_JJ
        elements_NNS play_VBP a_DT role_NN in_IN binding_VBG of_IN the_DT peptides_NNS to_TO TNFR_NNP 2_CD
        and_CC it_PRP may_MD be_VB that_IN the_DT peptides_NNS mimic_VBP rather_RB than_IN
        recapitulate_NN the_DT contact_NN domains_NNS of_IN the_DT natural_JJ ligands_NNS ._.
        ELISA_NNP analysis_NN showed_VBD that_IN all_DT four_CD phage_NN clones_NNS bound_VBN
        specifically_RB to_TO human_JJ TNFR_NNP 2_CD and_CC did_VBD not_RB react_VB with_IN either_DT
        human_NN or_CC murine_NN TNFR_NNP 1_CD or_CC murine_NN TNFR_NNP 2_CD (_( data_NNS not_RB shown_VBN )_) ._.
        Competition_NNP ELISAs_NNP were_VBD performed_VBN using_VBG TNFα_NNP and_CC TNFβ_NNP
        vs_NNS ._. the_DT four_CD phage_NN clones_NNS at_IN their_PRP$ ED_NNP 
        50_CD values_NNS (_( Figure_NN 1_CD a_DT ,_, 1_CD b_SYM ,_, 1_CD c_SYM ,_, 1_CD d_SYM )_) ._. More_JJR
        TNFα_NNP and_CC TNFβ_NNP were_VBD required_VBN to_TO compete_VB KcF_NNP 12_CD than_IN the_DT other_JJ
        phage_NN clones_NNS suggesting_VBG that_IN certain_JJ intrinsic_JJ properties_NNS
        of_IN KcF_NNP 12_CD (_( such_JJ as_IN its_PRP$ length_NN and_CC /_NN or_CC amino_JJ acid_NN content_NN )_) may_MD
        contribute_VB to_TO a_DT higher_JJR relative_JJ affinity_NN (_( Table_NNP 2_LS )_) ._. In_IN
        addition_NN ,_, the_DT synthetic_JJ forms_NNS of_IN KcC_NNP 7_CD ,_, KcD_NNP 11_CD ,_, KcF_NNP 6_CD and_CC the_DT
        recombinant_JJ KcF_NNP 12_CD (_( rKcF_NN 12_CD )_) were_VBD able_JJ to_TO compete_VB the_DT binding_JJ
        of_IN TNFα_NNP and_CC TNFβ_NNP ,_, as_RB well_RB as_IN KcF_NNP 6_CD and_CC KcF_NNP 12_CD phage_NN clones_NNS in_IN
        the_DT micromolar_NN range_NN (_( unpublished_JJ data_NNS )_) ._. Interestingly_RB ,_, the_DT
        three_CD 20_CD mer_NN HSPLs_NNP but_CC not_RB KcF_NNP 12_CD were_VBD competed_VBN by_IN an_DT
        anti-_NN TNFR_NNP 2_CD monoclonal_NN antibody_NN ,_, mAb_NN 226_CD ,_, (_( Figure_NN 2_LS )_)
        suggesting_VBG that_IN KCF_NNP 12_CD binds_NNS to_TO a_DT hotspot_NN on_IN TNFR_NNP 2_CD distinct_JJ
        from_IN the_DT other_JJ 3_CD peptides_NNS ._. A_DT summary_NN of_IN the_DT phage_NN /_NN peptide_NN
        competition_NN data_NNS is_VBZ shown_VBN in_IN Table_NNP 3_CD ._.
        Binding_NNP of_IN KcF_NNP 12_CD to_TO native_JJ TNFR_NNP 2_CD was_VBD measured_VBN in_IN Jurkat_NNP
        and_CC Jiyoye_NNP cells_NNS using_VBG a_DT radioreceptor_NN assay_NN ._. Jurkat_NNP cells_NNS
        have_VBP been_VBN reported_VBN to_TO have_VB approximately_RB equal_JJ numbers_NNS of_IN
        TNFR_NNP 1_CD and_CC TNFR_NNP 2_CD per_IN cell_NN [_NN 27_CD ]_NN whereas_IN Jiyoye_NNP cells_NNS
        express_VBP mainly_RB TNFR_NNP 2_CD (_( unpublished_JJ data_NNS )_) ._. KcF_NNP 12_CD inhibits_NNS
        TNFα_NNP binding_JJ to_TO Jiyoye_NNP cells_NNS with_IN a_DT Ki_NNP of_IN about_IN 2_CD uM_NN
        whereas_IN the_DT Ki_NNP for_IN the_DT peptide_NN in_IN Jurkat_NNP cells_NNS was_VBD found_VBN to_TO
        be_VB >_NN 30_CD uM_NN (_( Figure_NN 3_LS )_) ._. Since_IN TNFα_NNP binding_JJ to_TO Jurkat_NNP
        probably_RB involves_VBZ both_DT TNFR_NNP 1_CD and_CC TNFR_NNP 2_CD ,_, the_DT data_NNS offers_VBZ
        additional_JJ confirmation_NN of_IN KcF_NNP 12_CD 's_POS selectivity_NN for_IN
        TNFR_NNP 2_CD ._.
        It_PRP has_VBZ been_VBN previously_RB reported_VBN that_IN TNFα_NNP induced_VBD a_DT
        TNFR_NNP 2_CD -_: specific_JJ proliferation_NN of_IN the_DT neuroblastoma_NN cell_NN line_NN
        SK-N-BE_NNP [_NN 30_CD ]_NN ._. KcF_NNP 12_CD ,_, KcC_NNP 7_CD and_CC KcF_NNP 6_CD inhibited_VBD the_DT
        proliferative_JJ response_NN to_TO TNF-α_NNP in_IN this_DT cell_NN line_NN
        indicating_VBG that_IN they_PRP could_MD act_VB as_IN antagonists_NNS (_( data_NNS not_RB
        shown_VBN )_) ._. In_IN addition_NN ,_, the_DT same_JJ three_CD peptides_NNS were_VBD found_VBN to_TO
        be_VB cytotoxic_JJ to_TO SK-N-BE_NNP cells_NNS in_IN the_DT absence_NN of_IN TNFα_NNP
        (_( Figure_NN 4_CD a_DT )_) ._. KcF_NNP 12_CD possessed_VBD the_DT strongest_JJS killing_VBG activity_NN
        with_IN an_DT IC_NNP 
        50_CD of_IN ~_NN 700_CD nM_NN whereas_IN the_DT IC_NNP 
        50_CD s_VBZ for_IN KcC_NNP 7_CD and_CC KcF_NNP 6_CD were_VBD 2_CD uM_NN and_CC 7_CD
        uM_NN ,_, respectively_RB ._. None_NN of_IN the_DT peptides_NNS induced_VBD a_DT cytotoxic_JJ
        response_NN in_IN cell_NN lines_NNS not_RB expressing_VBG TNFR_NNP 2_CD (_( data_NNS not_RB
        shown_VBN )_) ._. Interestingly_RB ,_, KcD_NNP 11_CD ,_, which_WDT shares_VBZ a_DT motif_NN with_IN
        KcF_NNP 6_CD (_( Table_NNP 1_LS )_) ,_, had_VBD no_DT effect_NN on_IN SK-N-BE_NNP cells_NNS ._. The_DT absence_NN
        of_IN activity_NN by_IN KcD_NNP 11_CD did_VBD not_RB appear_VB to_TO be_VB due_JJ to_TO breakdown_NN
        of_IN the_DT peptide_NN during_IN culturing_VBG since_IN mass_NN spectral_NN
        analyses_NNS on_IN aliquots_NNS retrieved_VBD from_IN culture_NN media_NNS showed_VBD
        relatively_RB no_DT degradation_NN of_IN peptides_NNS between_IN the_DT initial_JJ
        and_CC the_DT final_JJ time_NN points_NNS (_( data_NNS not_RB shown_VBN )_) ._. Therefore_RB ,_, the_DT
        proliferation_NN data_NN suggests_VBZ evidence_NN of_IN a_DT hotspot_NN on_IN TNFR_NNP 2_CD
        recognized_VBN by_IN KcF_NNP 12_CD ,_, KcC_NNP 7_CD and_CC KcF_NNP 6_CD that_WDT is_VBZ linked_VBN to_TO this_DT
        unique_JJ biological_JJ effect_NN ._. The_DT inhibition_NN of_IN the_DT KcC_NNP 7_CD and_CC
        KcF_NNP 6_CD cytotoxic_JJ effect_NN with_IN mAb_NN 226_CD (_( Figure_NN 4_CD b_SYM )_) confirms_VBZ the_DT
        relationship_NN between_IN the_DT peptide-induced_JJ cytotoxic_JJ event_NN
        and_CC TNFR_NNP 2_CD because_IN of_IN the_DT antibody_NN 's_POS specificity_NN for_IN TNFR_NNP 2_CD ._.
        Overall_RB ,_, these_DT data_NNS indicate_VBP that_IN the_DT surface_NN topology_NN of_IN
        the_DT TNFR_NNP 2_CD binding_JJ site_NN is_VBZ very_RB complex_JJ and_CC may_MD be_VB composed_VBN
        of_IN multiple_JJ hotspots_NNS capable_JJ of_IN different_JJ regulatory_JJ
        functions_NNS ._.
      
      
        Discussion_NNP
        Peptide_NNP libraries_NNS have_VBP been_VBN successfully_RB used_VBN for_IN
        identifying_VBG novel_NN peptides_NNS mimicing_VBG natural_JJ molecules_NNS in_IN
        terms_NNS of_IN the_DT critical_JJ protein_NN :_: protein_NN interactions_NNS involved_VBN
        in_IN biological_JJ activity_NN ._. Yanofsky_NNP et_CC al_NN ._. [_NN 31_CD ]_NN described_VBD a_DT
        peptide_NN antagonist_NN to_TO IL-_NNP 1_CD that_WDT was_VBD active_JJ in_IN the_DT nM_NN range_NN
        and_CC Wrighton_NNP et_CC al_NN ._. and_CC Livnah_NNP et_CC al_NN ._. [_NN 32_CD 33_CD ]_NN identified_VBD
        peptides_NNS binding_VBG to_TO the_DT erythropoietin_NN (_( EPO_NNP )_) receptor_NN with_IN
        full_JJ agonist_NN activity_NN 
        in_IN vivo_NN ._. Neither_DT the_DT EPO_NNP agonist_NN nor_CC
        the_DT IL-_NNP 1_CD antagonist_NN peptides_NNS show_VBP any_DT significant_JJ sequence_NN
        homology_NN to_TO the_DT natural_JJ ligand_NN suggesting_VBG that_IN they_PRP act_VBP as_IN
        mimics_NNS of_IN the_DT natural_JJ ligand_NN ._. In_IN the_DT case_NN of_IN the_DT EPO_NNP
        agonists_NNS ,_, X-_NNP ray_NN crystallographic_JJ analysis_NN revealed_VBD that_IN one_CD
        of_IN these_DT peptides_NNS spontaneously_RB formed_VBN non-covalent_JJ
        homodimers_NNS that_WDT allowed_VBD the_DT dimerization_NN of_IN two_CD EPO_NNP
        receptors_NNS ._. Two_CD families_NNS of_IN small_JJ peptides_NNS binding_VBG to_TO the_DT
        human_JJ thrombopoietin_NN receptor_NN (_( TPOR_NNP )_) were_VBD isolated_VBN that_WDT
        competed_VBD with_IN the_DT natural_JJ ligand_NN TPO_NNP [_NN 34_CD ]_NN ._. The_DT peptide_NN
        with_IN the_DT highest_JJS affinity_NN was_VBD subsequently_RB dimerized_JJ and_CC
        shown_VBN to_TO function_VB as_IN a_DT potent_JJ TPO_NNP agonist_NN 
        in_IN vivo_NN ._. Recently_RB ,_, a_DT small_JJ ,_,
        non-peptide_JJ organic_JJ molecule_NN binding_JJ to_TO one_CD chain_NN of_IN the_DT
        EPO_NNP receptor_NN was_VBD multimerized_JJ and_CC shown_VBN to_TO mimic_VB the_DT
        biological_JJ activities_NNS of_IN the_DT EPO_NNP [_NN 35_CD ]_NN ._.
        In_IN this_DT report_NN we_PRP show_VBP that_IN HSPLs_NNP can_MD be_VB isolated_VBN that_DT
        bind_NN to_TO human_JJ TNFR_NNP 2_CD at_IN its_PRP$ ligand-binding_JJ site_NN and_CC
        subdivide_NN it_PRP into_IN multiple_JJ hotspots_NNS ._. All_DT of_IN the_DT peptides_NNS
        were_VBD competed_VBN by_IN both_DT TNFα_NNP and_CC TNFβ_NNP implying_VBG they_PRP
        recognized_VBD a_DT hotspot_NN that_WDT mapped_VBN either_DT within_IN or_CC at_IN least_JJS
        overlapping_VBG the_DT ligand-binding_JJ domain_NN of_IN TNFR_NNP 2_CD ._. The_DT HSPLs_NNP
        KcC_NNP 7_CD ,_, KcD_NNP 11_CD ,_, KcF_NNP 6_CD but_CC not_RB KcF_NNP 12_CD were_VBD also_RB inhibited_VBD by_IN the_DT
        neutralizing_VBG antibody_NN mAb_NN 226_CD suggesting_VBG the_DT 20_CD mers_NNS but_CC not_RB
        KcF_NNP 12_CD interact_NN with_IN a_DT hotspot_NN overlapping_VBG with_IN the_DT one_CD
        recognized_VBN by_IN antibody_NN ._. The_DT fact_NN that_IN recombinant_JJ KcF_NNP 12_CD
        peptide_NN competed_VBD all_DT of_IN the_DT phage_NN expressed_VBD peptides_NNS (_( Table_NNP
        3_LS )_) indicated_VBD that_IN the_DT four_CD peptides_NNS also_RB recognize_VBP a_DT common_JJ
        hotspot_NN which_WDT may_MD be_VB the_DT one_CD responsible_JJ for_IN TNF_NNP ligand_NN
        binding_VBG to_TO the_DT receptor_NN ._. In_IN addition_NN ,_, the_DT biological_JJ data_NN
        suggests_VBZ that_IN KcD_NNP 11_CD binds_NNS to_TO a_DT hotspot_NN that_WDT can_MD be_VB further_JJ
        separated_JJ from_IN KcF_NNP 12_CD ,_, KcF_NNP 6_CD and_CC KcC_NNP 7_CD ._. While_IN we_PRP cannot_NN rule_NN
        out_IN possible_JJ allosteric_JJ interactions_NNS between_IN the_DT peptides_NNS ,_,
        the_DT data_NNS suggests_VBZ that_IN the_DT HSPLs_NNP were_VBD able_JJ to_TO dissect_NN the_DT
        ligand-binding_JJ region_NN of_IN TNFR_NNP 2_CD into_IN several_JJ structural_JJ
        and_CC /_NN or_CC functional_JJ hotspots_NNS ._. In_IN addition_NN ,_, the_DT HSPLs_NNP were_VBD
        specific_JJ for_IN TNFR_NNP 2_CD unlike_IN the_DT native_JJ ligands_NNS TNF-α_NNP and_CC
        TNF-β_NNP which_WDT bind_NN to_TO both_DT receptors_NNS ._. These_DT results_NNS
        demonstrate_VBP that_IN the_DT approach_NN has_VBZ the_DT ability_NN to_TO dissect_NN
        critical_JJ protein_NN :_: protein_NN interaction_NN domains_NNS in_IN terms_NNS of_IN
        both_DT structural_JJ and_CC functional_JJ elements_NNS ._. Using_VBG a_DT similar_JJ
        approach_NN ,_, we_PRP recently_RB reported_VBD on_IN the_DT subdivision_NN of_IN the_DT
        ligand_NN binding_JJ domain_NN on_IN the_DT insulin_NN receptor_NN into_IN two_CD
        separate_JJ and_CC non-overlapping_JJ hotspots_NNS with_IN different_JJ
        biological_JJ activities_NNS [_NN 3_CD ]_NN ._.
        It_PRP has_VBZ been_VBN shown_VBN that_IN TNFα_NNP induced_VBD proliferation_NN of_IN the_DT
        undifferentiated_JJ neuroblastoma_NN cell_NN line_NN ,_, SK-N-BE_NNP ,_, resulted_VBD
        from_IN activation_NN of_IN TNFR_NNP 2_CD [_NN 30_CD ]_NN ._. Proliferation_NNP of_IN SK-N-BE_NNP
        cells_NNS could_MD be_VB suppressed_VBN by_IN the_DT pre-incubation_JJ of_IN cells_NNS
        with_IN anti-_NN TNFR_NNP 2_CD blocking_VBG antibodies_NNS without_IN concomitant_NN
        cytotoxicity_NN (_( data_NNS not_RB shown_VBN )_) ._. While_IN all_DT of_IN the_DT peptides_NNS
        blocked_VBD the_DT agonist_NN effects_NNS of_IN TNFα_NNP indicating_VBG that_IN they_PRP
        can_MD act_VB as_IN antagonists_NNS ,_, KcC_NNP 7_CD ,_, KcF_NNP 6_CD and_CC KcF_NNP 12_CD by_IN themselves_PRP
        induced_VBD a_DT cytotoxic_JJ response_NN by_IN killing_VBG SK-N-BE_NNP cells_NNS in_IN
        the_DT absence_NN of_IN TNFα_NNP ._. This_DT is_VBZ surprising_VBG because_IN these_DT
        peptides_NNS share_VBP a_DT hotspot_NN with_IN the_DT natural_JJ ligand_NN TNFα_NNP
        (_( which_WDT is_VBZ proliferative_JJ rather_RB than-cytotoxic_JJ )_) and_CC KcC_NNP 7_CD and_CC
        KcF_NNP 6_CD bind_NN to_TO a_DT hotspot_NN common_JJ to_TO the_DT neutralizing_VBG but_CC
        non-cytotoxic_JJ ,_, antibody_NN mAb_NN 226_CD ._. Overall_RB ,_, these_DT data_NNS suggest_VBP
        that_DT activation_NN (_( agonism_NN or_CC cytotoxicity_NN )_) of_IN TNFR_NNP 2_CD is_VBZ
        mediated_JJ through_IN unique_JJ hotspots_NNS on_IN the_DT receptor_NN that_WDT can_MD
        be_VB defined_VBN by_IN the_DT peptides_NNS ._. Under_IN the_DT present_JJ experimental_JJ
        conditions_NNS ,_, it_PRP is_VBZ unclear_JJ whether_IN the_DT natural_JJ ligand_NN ,_, TNFα_NNP ,_,
        touches_NNS the_DT hotspot_NN responsible_JJ for_IN cytotoxicity_NN although_IN
        one_PRP can_MD speculate_VB that_RB ,_, if_IN it_PRP does_VBZ ,_, the_DT cytotoxic_JJ effect_NN
        might_MD be_VB nullified_VBN by_IN the_DT sum_NN of_IN the_DT natural_JJ
        ligand_NN :_: receptor_NN interactions_NNS ._. Competition_NN experiments_NNS
        showing_VBG that_DT mAb_NN 226_CD reversed_VBD the_DT effects_NNS of_IN KcC_NNP 7_CD and_CC KcF_NNP 6_CD
        confirm_VB that_IN these_DT two_CD peptides_NNS induce_VB their_PRP$ effects_NNS though_IN
        their_PRP$ interaction_NN with_IN TNFR_NNP 2_CD ._. These_DT findings_NNS suggest_VBP that_IN
        TNFR_NNP 2_CD has_VBZ multiple_JJ biological_JJ functions_NNS ._. In_IN addition_NN to_TO
        transferring_VBG TNFα_NNP to_TO TNFR_NNP 1_CD as_IN proposed_VBN by_IN the_DT ligand_NN
        passing_VBG model_NN [_NN 36_CD ]_NN ,_, TNFR_NNP 2_CD may_MD have_VB a_DT role_NN in_IN modulating_VBG
        proliferative_JJ responses_NNS in_IN both_DT positive_JJ and_CC negative_JJ
        manner_NN ._. Ongoing_NNP studies_NNS will_MD attempt_VB to_TO elucidate_NN the_DT
        mechanism_NN of_IN action_NN behind_IN the_DT phenomenon_NN such_JJ as_IN the_DT
        effects_NNS on_IN downstream_JJ signaling_VBG pathways_NNS including_VBG NFkB_NNP ,_,
        and_CC apoptosis_NNS ._. However_RB ,_, it_PRP is_VBZ possible_JJ that_IN peptide-induced_JJ
        cytotoxicity_NN works_VBZ through_IN a_DT mechanism_NN similar_JJ to_TO TNF_NNP
        mediated_JJ apoptosis_NNS in_IN T-_NNP cells_NNS [_NN 37_CD ]_NN ._.
      
      
        Conclusions_NNP
        In_IN summary_NN ,_, HSPLs_NNP were_VBD isolated_VBN with_IN which_WDT we_PRP were_VBD able_JJ
        to_TO dissect_NN the_DT ligand-binding_JJ domain_NN of_IN a_DT natural_JJ receptor_NN
        and_CC generate_VB information_NN about_IN novel_NN and_CC unexpected_JJ
        bioactivities_NNS ._. This_DT technology_NN has_VBZ also_RB been_VBN successfully_RB
        used_VBN for_IN known_VBN protein_NN targets_NNS ,_, such_JJ as_IN the_DT insulin_NN
        receptor_NN [_NN 3_CD ]_NN and_CC TNF-β_NNP [_NN 38_CD ]_NN as_RB well_RB as_IN non-protein_JJ
        targets_NNS such_JJ as_IN disease-specific_JJ RNAs_NNP [_NN 38_CD ]_NN ._. We_PRP have_VBP also_RB
        shown_VBN that_IN the_DT HSPL_NNP libraries_NNS identify_VBP hotspots_NNS on_IN novel_NN
        genes_NNS of_IN unknown_JJ function_NN and_CC identify_VB functional_JJ
        interaction_NN pathways_NNS (_( manuscript_NN in_IN preparation_NN )_) ._. Overall_RB ,_,
        the_DT use_NN of_IN HSPLs_NNP have_VBP the_DT potential_NN to_TO become_VB a_DT general_JJ
        approach_NN for_IN scanning_VBG and_CC understanding_VBG complex_JJ
        protein_NN :_: protein_NN interactions_NNS ._.
      
      
        Methods_NNP
        
          Materials_NNS
          
          E_NNP ._. coli_NNS ,_, strain_NN TG_NNP 1_CD (_( genotype_NN =_SYM
          K_NNP 12_CD Δ_NN 
          (_( lac-pro_JJ )_) ,_, supE_NN ,_, thi_NN ,_, hsdΔ_NN 5_CD /_NN F_NN '_'' [_NN traD_NN 36_CD ,_,
          proAB_NN ,_, 
          lacI_NN 
          q_NN ,_, 
          lacZΔM_NN 15_CD ]_NN )_) was_VBD obtained_VBN from_IN
          Pharmacia_NNP (_( Piscataway_NNP ,_, NJ_NNP )_) ._. Recombinant_NNP human_JJ Tumor_NNP
          Necrosis_NNP Factor-α_NNP (_( rhTNFα_NN )_) was_VBD purchased_VBN from_IN R_NN &_CC D_NNP
          Systems_NNPS ,_, Inc_NNP ._. (_( Minneapolis_NNP ,_, MN_NNP )_) or_CC PeproTech_NNP Inc_NNP ._. (_( Rocky_NNP
          Hill_NNP ,_, NJ_NNP )_) ._. Monoclonal_NNP antibodies_NNS against_IN recombinant_JJ
          human_JJ soluble_JJ TNF_NNP receptor_NN RI_NNP (_( mAb_NN 225_CD )_) and_CC RII_NNP (_( mAb_NN 226_CD )_)
          were_VBD purchased_VBN from_IN R_NN &_CC D_NNP Systems_NNPS ,_, Inc_NNP ._. (_( Minneapolis_NNP ,_,
          MN_NNP )_) ._. WST-_NNP 1_CD was_VBD purchased_VBN from_IN Roche_NNP (_( Nutley_NNP ,_, NJ_NNP )_) ._.
          125_CD I-TNF_NNP α_NN (_( NEX_NNP 257_CD )_) with_IN a_DT specific_JJ activity_NN of_IN 97_CD μCi_NN /_NN μg_NN
          (_( 1698_CD Ci_NNP /_NN mmol_NN )_) was_VBD purchased_VBN from_IN NEN_NNP Life_NNP Science_NNP
          Products_NNPS ,_, Inc_NNP (_( Boston_NNP ,_, MA_NNP )_) ._. Beckman_NNP Ready_NNP Safe_NNP ™_NN
          scintillation_NN fluid_NN was_VBD purchased_VBN from_IN Beckman_NNP Coulter_NNP ,_,
          Inc_NNP ._. (_( Fullerton_NNP ,_, CA_NNP )_) ._. MultiSreen_NNP ™_NN assay_NN filter_NN plate_NN
          system_NN and_CC 96_CD -_: well_RB MultiScreen_NNP ®_NN MAFC_NNP filter_NN plates_NNS were_VBD
          from_IN Millipore_NNP (_( Bedford_NNP ,_, MA_NNP )_) ._. RPMI_NNP 1640_CD media_NNS ,_, fetal_JJ
          bovine_JJ serum_NN ,_, and_CC GlutaMAX_NNP ™_NN -_: I_PRP were_VBD obtained_VBN from_IN Life_NNP
          Technologies_NNPS (_( Rockville_NNP ,_, MD_NNP )_) ._. Polyvinylpyrrolidone_NNP (_( PVP_NNP )_) ,_,
          Tween-_NNP 20_CD R_NN ™_NN ,_, phosphate-buffered_JJ saline_NN (_( PBS_NNP )_) ,_, and_CC
          Dulbecco_NNP 's_POS phosphate-buffered_JJ saline_NN (_( containing_VBG no_DT
          calcium_NN or_CC magnesium_NN )_) were_VBD purchased_VBN from_IN Sigma_NNP Chemical_NNP
          Co_NNP ._. (_( St_NNP ._. Louis_NNP ,_, MO_NNP )_) ._. All_DT other_JJ chemicals_NNS and_CC reagents_NNS
          used_VBN were_VBD analytical_JJ grade_NN ._.
        
        
          Cell_NNP Culture_NNP
          SK-N-BE_NNP neuroblastoma_NN cells_NNS ,_, Jurkat_NNP (_( TIB-_NNP 152_CD )_) and_CC
          Jiyoye_NNP (_( CCL-_NNP 87_CD )_) cells_NNS were_VBD obtained_VBN from_IN the_DT ATCC_NNP
          (_( Manassas_NNP ,_, VA_NNP )_) ._. SK-N-BE_NNP and_CC Jurkat_NNP cells_NNS were_VBD maintained_VBN
          in_IN RPMI_NNP 1640_CD media_NNS supplemented_JJ with_IN 10_CD %_NN fetal_JJ bovine_JJ
          serum_NN (_( FBS_NNP )_) and_CC 2_CD mM_NN GlutaMAX_NNP ™_NN -_: I_PRP ,_, while_IN Jiyoye_NNP cells_NNS were_VBD
          maintained_VBN in_IN RPMI_NNP 1640_CD media_NNS supplemented_JJ with_IN 15_CD %_NN FBS_NNP
          and_CC 2_CD mM_NN GlutaMAX_NNP ™_NN ._.
        
        
          Design_NNP of_IN the_DT Primary_JJ Peptide_NNP Libraries_NNP
          A_DT description_NN of_IN library_NN design_NN and_CC production_NN has_VBZ
          been_VBN previously_RB published_VBN [_NN 3_CD 28_CD ]_NN ._.
        
        
          Subtractive_NNP Panning_NNP and_CC ELISA_NNP
          Panning_NNP was_VBD done_VBN as_IN described_VBN [_NN 3_CD 28_CD ]_NN ,_, except_IN that_DT
          only_RB 6_CD wells_NNS of_IN a_DT 96_CD -_: well_RB microtiter_NN plate_NN were_VBD coated_VBN
          with_IN target_NN at_IN concentrations_NNS ranging_VBG from_IN 10_CD -_: 100_CD
          ng_NN /_NN well_RB ._. The_DT cross_NN reactive_JJ phages_NNS from_IN the_DT eluted_JJ phage_NN
          were_VBD then_RB subtracted_VBN by_IN panning_VBG sequentially_RB against_IN
          human_JJ TNFR_NNP 1_CD ,_, TNFα_NNP and_CC TNFβ_NNP as_IN a_DT way_NN to_TO obtain_VB peptides_NNS
          specific_JJ to_TO the_DT original_JJ target_NN ._. ELISA_NNP was_VBD done_VBN as_IN
          previous_JJ described_VBD [_NN 3_CD 28_CD ]_NN ._.
        
        
          Phage_NNP Competition_NNP ELISA_NNP Studies_NNPS
          Target_NNP was_VBD coated_JJ on_IN MaxiSorp_NNP plates_NNS and_CC blocked_VBN with_IN
          NFM-PBS_NNP as_IN described_VBN [_NN 3_CD 28_CD ]_NN ._. HSPLs_NNP (_( phage_NN clones_NNS or_CC
          synthetic_JJ peptides_NNS )_) are_VBP added_VBN in_IN the_DT presence_NN of_IN varying_VBG
          concentrations_NNS of_IN competitor_NN (_( e_SYM ._. g_SYM ._. ,_, TNF_NNP ligand_NN or_CC soluble_JJ
          receptor_NN )_) ._. IC_NNP 
          50_CD s_VBZ are_VBP determined_VBN by_IN probing_VBG for_IN
          phage_NN or_CC peptide_NN binding_JJ to_TO target_VB in_IN the_DT presence_NN of_IN
          competitor_NN ._.
        
        
          Receptor_NNP Binding_NNP and_CC Competition_NNP Assay_NNP
          The_DT binding_JJ of_IN TNFα_NNP to_TO TNFR_NNP 2_CD on_IN intact_JJ cells_NNS was_VBD
          measured_VBN in_IN a_DT radioareceptor_NN assay_NN using_VBG Jurkat_NNP and_CC
          Jiyoye_NNP cells_NNS and_CC the_DT MultiSreen_NNP ™_NN assay_NN filter_NN plate_NN
          system_NN as_IN described_VBN [_NN 39_CD ]_NN ._. Data_NNP analysis_NN was_VBD performed_VBN
          with_IN an_DT add-in_JJ for_IN Microsoft_NNP Excel_NNP ,_, Xlfit_NNP ™_NN (_( version_NN 2_CD ._. 0_CD )_)
          from_IN ID_NNP Business_NNP Solutions_NNPS (_( Guildford_NNP ,_, UK_NNP )_) ,_, which_WDT allows_VBZ
          curve_NN fitting_JJ using_VBG nonlinear_NN regression_NN ._. To_TO determine_VB
          binding_JJ kinetic_JJ parameters_NNS ,_, the_DT Four-_NNP Parameter_NNP logistic_JJ
          equation_NN y_NN =_SYM Bottom_NNP +_NN (_( Top_JJ -_: Bottom_NNP )_) /_NN (_( 1_CD +_NN (_( IC_NNP 
          50_CD /_NN x_SYM )_) Hill_NNP slope_NN )_) was_VBD used_VBN to_TO
          calculate_VB IC_NNP 
          50_CD values_NNS and_CC Hill_NNP slopes_NNS ._. K_NNP 
          i_NNP values_NNS were_VBD calculated_VBN according_VBG to_TO
          the_DT equation_NN ,_, K_NNP 
          i_NNP =_SYM IC_NNP 
          50_CD /_NN (_( 1_CD +_NN [_NN ligand_NN ]_NN /_NN K_NNP 
          d_SYM )_) ,_, as_IN described_VBN by_IN Cheng_NNP and_CC Prusoff_NNP
          [_NN 40_CD ]_NN ._.
        
        
          Proliferation_NNP cell_NN assay_NN
          SK-N-BE_NNP cells_NNS were_VBD seeded_VBN loosely_RB in_IN 96_CD well_RB plates_NNS in_IN
          SK-N-BE_NNP medium_NN and_CC allowed_VBN to_TO grow_VB to_TO 75_CD -_: 80_CD %_NN confluency_NN ._.
          Cells_NNP were_VBD starved_VBN overnight_JJ in_IN media_NNS containing_VBG 1_CD %_NN serum_NN
          before_IN each_DT cell_NN experiment_NN ._. Briefly_NNP ,_, cells_NNS were_VBD first_RB
          treated_VBN with_IN a_DT human_JJ TNFR_NNP 1_CD blocking_VBG mAb_NN ,_, mAb_NN 225_CD (_( 10_CD
          ug_NN /_NN ml_NN )_) ,_, for_IN at_IN least_JJS 30_CD min_NN at_IN 37_CD C_NNP prior_RB to_TO the_DT addition_NN
          of_IN agents_NNS ._. All_DT agents_NNS used_VBN in_IN the_DT cell_NN experiment_NN were_VBD
          serial_NN diluted_VBN at_IN 1_CD :_: 2_CD and_CC mixed_JJ in_IN a_DT separate_JJ plate_NN
          before_IN transferring_VBG into_IN the_DT actual_JJ cell_NN plate_NN ._. The_DT
          starting_VBG highest_JJS final_JJ concentration_NN of_IN each_DT peptide_NN was_VBD
          at_IN 30_CD uM_NN or_CC at_IN its_PRP$ highest_JJS possible_JJ concentration_NN ._. Cells_NNP
          were_VBD then_RB returned_VBN into_IN the_DT incubator_NN for_IN 40_CD -_: 45_CD hrs_NNS
          before_IN the_DT addition_NN of_IN 1_CD /_NN 10_CD vol_NN of_IN WST-_NNP 1_CD ._. The_DT plates_NNS were_VBD
          further_JJ incubated_JJ and_CC developed_VBN according_VBG to_TO the_DT
          manufacturer_NN 's_POS instruction_NN ._.
        
      
      
        Authors_NNP '_'' Contributions_NNP
        KcH_NNP isolated_VBD and_CC characterized_VBD the_DT HSPLs_NNP binding_JJ to_TO
        TNFR_NNP 2_CD ._. RB_NNP prepared_VBD the_DT primary_JJ and_CC secondary_JJ HSPL_NNP
        libraries_NNS ._. PW_NNP and_CC ML_NNP produced_VBD and_CC purified_JJ the_DT recombinant_JJ
        peptides_NNS and_CC performed_VBD the_DT stability_NN studies_NNS with_IN the_DT
        peptides_NNS ._. PF_NNP and_CC VR_NNP did_VBD the_DT binding_JJ assays_NNS ._. AB_NNP contributed_VBD
        helpful_JJ suggestions_NNS about_IN the_DT design_NN of_IN the_DT studies_NNS ._. NG_NNP
        conceived_VBD the_DT study_NN and_CC participated_VBD in_IN the_DT design_NN and_CC
        coordination_NN of_IN the_DT experiments_NNS ._. All_DT authors_NNS have_VBP read_VBN and_CC
        approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
